StudyFinder

VX21-522-001: A Phase 1 Multiple Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

Recruiting

This is a clinical research study exploring the safety and tolerability of a single dose of VX-522 for people with cystic fibrosis (CF) who are not expected to benefit from CFTR modulators.

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 65 years old
• Stable cystic fibrosis disease
• FEV1 at least 40%
• Specific CFTR gene mutations
Exclusion Criteria:

• Uncontrolled asthma in the last year
• Oxygen saturation without oxygen therapy is >94%
• Severe liver disease

Drug: IVA, Drug: VX-522 mRNA therapy

Rare Diseases, Breathing, Lung & Sleep Health

Cystic Fibrosis, CF

Mary Bailey - mpbailey@umn.edu
Joanne Billings
PHASE1
SITE00001585
See this study on ClinicalTrials.gov

Back